TRIO Pharmaceuticals Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$3.1M
- Investors
-
7
TRIO Pharmaceuticals General Information
Description
Developer of novel bispecific antibody drugs designed to generate immunogenic tumors. The company's drug offers dual-action tumor immunity-enhancing qualities aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells, enabling physicians to improve efficacy, reduce toxicity, and increase treatment affordability.
Contact Information
Website
www.triopharmaceuticals.comCorporate Office
- 930 Brittan Avenue
- San Carlos
- San Francisco, CA 94070
- United States
Corporate Office
- 930 Brittan Avenue
- San Carlos
- San Francisco, CA 94070
- United States
TRIO Pharmaceuticals Timeline
TRIO Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 07-Nov-2024 | $3.1M | Completed | Pre-Clinical Trials | ||
| 2. Seed Round | 31-Mar-2023 | Completed | Startup | |||
| 1. Grant | 01-Sep-2022 | $800K | Completed | Startup |
TRIO Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Pre-Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TRIO Pharmaceuticals Patents
TRIO Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026534883-A | Target activation of endogenous cell death | Pending | 25-Sep-2023 | ||
| AU-2024350163-A1 | Targeted activation of endogenous cell death | Pending | 25-Sep-2023 | ||
| EP-4784625-A2 | Targeted activation of endogenous cell death | Pending | 25-Sep-2023 | ||
| WO-2025072182-A2 | Targeted activation of endogenous cell death | Inactive | 25-Sep-2023 | ||
| WO-2025072182-A3 | Targeted activation of endogenous cell death | Inactive | 25-Sep-2023 | A61K31/635 |
TRIO Pharmaceuticals Signals
TRIO Pharmaceuticals Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Myeloma Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| Friedman BioVentures | Venture Capital | Minority | ||
| NuFund Venture Group | Angel Group | Minority | ||
| Purdue Ventures | Not-For-Profit Venture Capital | Minority | ||
| SeedFolio | Venture Capital | Minority |
TRIO Pharmaceuticals FAQs
-
When was TRIO Pharmaceuticals founded?
TRIO Pharmaceuticals was founded in 2020.
-
Where is TRIO Pharmaceuticals headquartered?
TRIO Pharmaceuticals is headquartered in San Francisco, CA.
-
What is the size of TRIO Pharmaceuticals?
TRIO Pharmaceuticals has 9 total employees.
-
What industry is TRIO Pharmaceuticals in?
TRIO Pharmaceuticals’s primary industry is Drug Discovery.
-
Is TRIO Pharmaceuticals a private or public company?
TRIO Pharmaceuticals is a Private company.
-
What is the current valuation of TRIO Pharmaceuticals?
The current valuation of TRIO Pharmaceuticals is .
-
What is TRIO Pharmaceuticals’s current revenue?
The current revenue for TRIO Pharmaceuticals is .
-
How much funding has TRIO Pharmaceuticals raised over time?
TRIO Pharmaceuticals has raised $5.7M.
-
Who are TRIO Pharmaceuticals’s investors?
Myeloma Investment Fund, Friedman BioVentures, NuFund Venture Group, Purdue Ventures, and SeedFolio are 5 of 7 investors who have invested in TRIO Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process